Oculis Holding AG
Social media
Oculis Holding AG Logo
About Oculis Holding AG
Oculis Holding AG is a clinical-stage biopharmaceutical company based in Switzerland, dedicated to developing innovative treatments for ophthalmic diseases. Its pipeline includes OCS-01, a topical dexamethasone formulation for diabetic macular edema; OCS-02, a biologic candidate for dry eye disease; and OCS-05, a neuroprotective agent for neuro-ophthalmic conditions such as glaucoma and acute optic neuritis. Oculis aims to address unmet medical needs in eye care with differentiated, non-invasive therapies and serves patients worldwide.
Address
Bahnhofstrasse 7,
Zug, 6300
Switzerland
Year founded
1970
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
